Favezelimab, an anti-LAG-3 antibody, in combination with pembrolizumab, demonstrated promising activity in patients with heavily pretreated, anti-PD-1-refractory classical cHL in early-phase clinical studies. The gene discussed is LAG3; the disease is classic Hodgkin lymphoma.